vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and TSS, Inc. (TSSI). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $60.9M, roughly 15.6× TSS, Inc.). TSS, Inc. runs the higher net margin — 20.0% vs 0.7%, a 19.3% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 21.8%). TSS, Inc. produced more free cash flow last quarter ($15.8M vs $-6.0M). Over the past eight quarters, TSS, Inc.'s revenue compounded faster (95.8% CAGR vs 53.3%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

ASTH vs TSSI — Head-to-Head

Bigger by revenue
ASTH
ASTH
15.6× larger
ASTH
$950.5M
$60.9M
TSSI
Growing faster (revenue YoY)
ASTH
ASTH
+21.1% gap
ASTH
42.9%
21.8%
TSSI
Higher net margin
TSSI
TSSI
19.3% more per $
TSSI
20.0%
0.7%
ASTH
More free cash flow
TSSI
TSSI
$21.7M more FCF
TSSI
$15.8M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
TSSI
TSSI
Annualised
TSSI
95.8%
53.3%
ASTH

Income Statement — Q4 2025 vs Q4 2025

Metric
ASTH
ASTH
TSSI
TSSI
Revenue
$950.5M
$60.9M
Net Profit
$6.6M
$12.2M
Gross Margin
17.6%
Operating Margin
1.9%
1.5%
Net Margin
0.7%
20.0%
Revenue YoY
42.9%
21.8%
Net Profit YoY
184.4%
535.7%
EPS (diluted)
$0.12
$0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
TSSI
TSSI
Q4 25
$950.5M
$60.9M
Q3 25
$956.0M
$41.9M
Q2 25
$654.8M
$44.0M
Q1 25
$620.4M
$99.0M
Q4 24
$665.2M
$50.0M
Q3 24
$478.7M
$70.1M
Q2 24
$486.3M
$12.2M
Q1 24
$404.4M
$15.9M
Net Profit
ASTH
ASTH
TSSI
TSSI
Q4 25
$6.6M
$12.2M
Q3 25
$373.0K
$-1.5M
Q2 25
$9.4M
$1.5M
Q1 25
$6.7M
$3.0M
Q4 24
$-7.8M
$1.9M
Q3 24
$16.1M
$2.6M
Q2 24
$19.2M
$1.4M
Q1 24
$14.8M
$15.0K
Gross Margin
ASTH
ASTH
TSSI
TSSI
Q4 25
17.6%
Q3 25
11.1%
Q2 25
17.8%
Q1 25
9.3%
Q4 24
14.4%
Q3 24
11.3%
Q2 24
37.3%
Q1 24
17.1%
Operating Margin
ASTH
ASTH
TSSI
TSSI
Q4 25
1.9%
1.5%
Q3 25
2.0%
-2.2%
Q2 25
3.1%
5.1%
Q1 25
3.3%
4.2%
Q4 24
0.1%
0.0%
Q3 24
5.9%
5.4%
Q2 24
6.2%
14.0%
Q1 24
7.5%
1.6%
Net Margin
ASTH
ASTH
TSSI
TSSI
Q4 25
0.7%
20.0%
Q3 25
0.0%
-3.6%
Q2 25
1.4%
3.4%
Q1 25
1.1%
3.0%
Q4 24
-1.2%
3.8%
Q3 24
3.4%
3.8%
Q2 24
3.9%
11.5%
Q1 24
3.7%
0.1%
EPS (diluted)
ASTH
ASTH
TSSI
TSSI
Q4 25
$0.12
$0.44
Q3 25
$0.01
$-0.06
Q2 25
$0.19
$0.06
Q1 25
$0.14
$0.12
Q4 24
$-0.14
$0.08
Q3 24
$0.33
$0.10
Q2 24
$0.40
$0.06
Q1 24
$0.31
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
TSSI
TSSI
Cash + ST InvestmentsLiquidity on hand
$429.5M
$85.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$76.6M
Total Assets
$2.2B
$184.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
TSSI
TSSI
Q4 25
$429.5M
$85.5M
Q3 25
$463.4M
$70.7M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
$23.2M
Q3 24
$350.3M
$46.4M
Q2 24
$327.7M
$8.3M
Q1 24
$337.3M
$14.4M
Stockholders' Equity
ASTH
ASTH
TSSI
TSSI
Q4 25
$779.3M
$76.6M
Q3 25
$775.5M
$63.4M
Q2 25
$765.5M
$9.5M
Q1 25
$745.4M
$9.4M
Q4 24
$712.7M
$7.1M
Q3 24
$704.6M
$7.7M
Q2 24
$678.9M
$5.2M
Q1 24
$653.5M
$3.7M
Total Assets
ASTH
ASTH
TSSI
TSSI
Q4 25
$2.2B
$184.9M
Q3 25
$2.2B
$165.4M
Q2 25
$1.4B
$139.5M
Q1 25
$1.3B
$113.5M
Q4 24
$1.4B
$96.6M
Q3 24
$1.3B
$67.3M
Q2 24
$1.3B
$28.9M
Q1 24
$1.2B
$26.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
TSSI
TSSI
Operating Cash FlowLast quarter
$-2.9M
$16.3M
Free Cash FlowOCF − Capex
$-6.0M
$15.8M
FCF MarginFCF / Revenue
-0.6%
25.9%
Capex IntensityCapex / Revenue
0.3%
0.9%
Cash ConversionOCF / Net Profit
-0.44×
1.34×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
TSSI
TSSI
Q4 25
$-2.9M
$16.3M
Q3 25
$10.0M
$-18.4M
Q2 25
$90.9M
$16.3M
Q1 25
$16.6M
$20.6M
Q4 24
$-10.9M
$-21.6M
Q3 24
$34.0M
$38.6M
Q2 24
$23.2M
$-4.3M
Q1 24
$6.0M
$2.6M
Free Cash Flow
ASTH
ASTH
TSSI
TSSI
Q4 25
$-6.0M
$15.8M
Q3 25
$7.4M
$-24.9M
Q2 25
$89.5M
$5.4M
Q1 25
$13.6M
$5.8M
Q4 24
$-13.5M
$-28.4M
Q3 24
$31.7M
$38.6M
Q2 24
$20.4M
$-6.0M
Q1 24
$5.6M
$2.6M
FCF Margin
ASTH
ASTH
TSSI
TSSI
Q4 25
-0.6%
25.9%
Q3 25
0.8%
-59.3%
Q2 25
13.7%
12.3%
Q1 25
2.2%
5.8%
Q4 24
-2.0%
-56.7%
Q3 24
6.6%
55.1%
Q2 24
4.2%
-49.4%
Q1 24
1.4%
16.4%
Capex Intensity
ASTH
ASTH
TSSI
TSSI
Q4 25
0.3%
0.9%
Q3 25
0.3%
15.3%
Q2 25
0.2%
24.8%
Q1 25
0.5%
15.0%
Q4 24
0.4%
13.4%
Q3 24
0.5%
0.1%
Q2 24
0.6%
13.8%
Q1 24
0.1%
0.2%
Cash Conversion
ASTH
ASTH
TSSI
TSSI
Q4 25
-0.44×
1.34×
Q3 25
26.69×
Q2 25
9.65×
11.02×
Q1 25
2.48×
6.93×
Q4 24
-11.32×
Q3 24
2.11×
14.60×
Q2 24
1.21×
-3.09×
Q1 24
0.40×
176.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

TSSI
TSSI

Procurement Revenues Segment$43.2M71%
System Integration Services Segment$14.2M23%
Facilities Segment$3.5M6%

Related Comparisons